what will it take to ignite the cannon?

No way this company is going to sit at this SP for much longer.

Quality, world class personel, with proven records of getting products to market.

Very exciting times with R-Salbutomol, especially if you compare it to ractopamine, a potential competitor. Potential for huge revenues

Immunoxel- Also very exciting with current studies underway in the US, Nigeria and Ukraine with results due this year. Both the market for drugs in HIV and tuberculosis is huge. Already published highly successful results.

Not to count sales already in OZ, a pharma plant in Canada, relationship with Kidney Health Aust and coming joint product, future sales and current product partnerships in the US and not to count the drug inhalation device........the list goes on!

All for less than 9million m/c

How have we attracted quality personnel to such a small company? and P Boonen picked up a few shares on market a few weeks back. Bring on institutional investors!